Clinical Use of On-Demand Therapies for Patients with Parkinson's Disease and OFF Periods

被引:1
作者
Pahwa, Rajesh [1 ]
Pagan, Fernando L. [2 ]
Kremens, Daniel E. [3 ]
Saint-Hilaire, Marie [4 ]
机构
[1] Univ Kansas, Dept Neurol, Med Ctr, 3599 Rainbow Blvd,Mailstop 2012, Kansas City, KS 66160 USA
[2] Georgetown Univ Hosp, Dept Neurol, Washington, DC USA
[3] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA USA
[4] Boston Univ, Parkinsons Dis & Movement Disorders Ctr, Dept Neurol, Sch Med, Boston, MA USA
关键词
Apomorphine; Levodopa; On-demand therapy; Parkinson's disease; Rescue therapy; QUALITY STANDARDS SUBCOMMITTEE; PLACEBO-CONTROLLED TRIAL; MOTOR FLUCTUATIONS; DOUBLE-BLIND; PRACTICE PARAMETER; AMERICAN-ACADEMY; SUBCUTANEOUS APOMORPHINE; NONMOTOR FLUCTUATIONS; LEVODOPA THERAPY; WEARING-OFF;
D O I
10.1007/s40120-023-00486-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
On-demand therapies for Parkinson's disease (PD) provide rapid, reliable relief for patients experiencing OFF periods; however, practical guidelines on the use of these therapies are not generally available. This paper reviews the use of on-demand treatments. Motor fluctuations occur in nearly all patients with PD after long-term use of levodopa. As the goal of PD treatment is to provide good ON time, on-demand treatments that have a more rapid reliable onset than the slower-acting oral medications provide rapid relief for OFF periods. All current on-demand treatments bypass the gastrointestinal tract, providing dopaminergic therapy directly into the blood stream by subcutaneous injection, through the buccal mucosa, or by inhalation into the pulmonary circulation. On-demand treatments are fast acting (10- to 20-min onset), with maximum, reliable, and significant responses reached within 30 min after administration. Oral medications pass through the gastrointestinal tract and thus have slower absorption owing to gastroparesis and competition with food. On-demand therapies, by providing fast-acting relief, can have a positive impact on a patient's quality of life when patients are experiencing OFF periods.
引用
收藏
页码:1033 / 1049
页数:17
相关论文
共 87 条
  • [1] Acorda Therapeutics Inc., 2022, INBR LEV INH POWD OR
  • [2] A real-world study of wearable sensors in Parkinson's disease
    Adams, Jamie L.
    Dinesh, Karthik
    Snyder, Christopher W.
    Xiong, Mulin
    Tarolli, Christopher G.
    Sharma, Saloni
    Dorsey, E. Ray
    Sharma, Gaurav
    [J]. NPJ PARKINSONS DISEASE, 2021, 7 (01)
  • [3] Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa
    Adler, CH
    Singer, C
    O'Brien, C
    Hauser, RA
    Lew, MF
    Marek, KL
    Dorflinger, E
    Pedder, S
    Deptula, D
    Yoo, K
    [J]. ARCHIVES OF NEUROLOGY, 1998, 55 (08) : 1089 - 1095
  • [4] Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
    Ahlskog, JE
    Muenter, MD
    [J]. MOVEMENT DISORDERS, 2001, 16 (03) : 448 - 458
  • [5] American Academy of Neurology, PARK DIS QUAL MEAS S
  • [6] [Anonymous], 2020, MED LETT DRUGS THER, V62, P165
  • [7] Medical and Surgical Management of Advanced Parkinson's Disease
    Antonini, Angelo
    Moro, Elena
    Godeiro, Clecio
    Reichmann, Heinz
    [J]. MOVEMENT DISORDERS, 2018, 33 (06) : 900 - 908
  • [8] Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations
    Carbone, Federico
    Djamshidian, Atbin
    Seppi, Klaus
    Poewe, Werner
    [J]. CNS DRUGS, 2019, 33 (09) : 905 - 918
  • [9] Delayed early morning turn "ON'' in response to a single dose of levodopa in advanced Parkinson's disease:: pharmacokinetics should be considered
    Chaná, P
    Kuntsmann, C
    Reyes-Parada, M
    Sáez-Briones, P
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2004, 75 (12) : 1782 - 1783
  • [10] Wearable Solutions for Patients with Parkinson's Disease and Neurocognitive Disorder: A Systematic Review
    Channa, Asma
    Popescu, Nirvana
    Ciobanu, Vlad
    [J]. SENSORS, 2020, 20 (09)